Cargando…

Immune profile of primary and recurrent epithelial ovarian cancer cases indicates immune suppression, a major cause of progression and relapse of ovarian cancer

BACKGROUND: Ovarian cancer is the third most prevalent cancer in Indian women. Relative frequency of High grade serous epithelial ovarian cancer (HGSOC) and its associated deaths are highest in India which suggests the importance of understanding their immune profiles for better treatment modality....

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Pavan, Ranmale, Samruddhi, Mehta, Sanket, Tongaonkar, Hemant, Patel, Vainav, Singh, Amit Kumar, Mania-Pramanik, Jayanti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10268537/
https://www.ncbi.nlm.nih.gov/pubmed/37322531
http://dx.doi.org/10.1186/s13048-023-01192-4
_version_ 1785059110719324160
author Kumar, Pavan
Ranmale, Samruddhi
Mehta, Sanket
Tongaonkar, Hemant
Patel, Vainav
Singh, Amit Kumar
Mania-Pramanik, Jayanti
author_facet Kumar, Pavan
Ranmale, Samruddhi
Mehta, Sanket
Tongaonkar, Hemant
Patel, Vainav
Singh, Amit Kumar
Mania-Pramanik, Jayanti
author_sort Kumar, Pavan
collection PubMed
description BACKGROUND: Ovarian cancer is the third most prevalent cancer in Indian women. Relative frequency of High grade serous epithelial ovarian cancer (HGSOC) and its associated deaths are highest in India which suggests the importance of understanding their immune profiles for better treatment modality. Hence, the present study investigated the NK cell receptor expression, their cognate ligands, serum cytokines, and soluble ligands in primary and recurrent HGSOC patients. We have used multicolor flow cytometry for immunophenotyping of tumor infiltrated and circulatory lymphocytes. Procartaplex, and ELISA were used to measure soluble ligands and cytokines of HGSOC patients. RESULTS: Among the enrolled 51 EOC patients, 33 were primary high grade serous epithelial ovarian cancer (pEOC) and 18 were recurrent epithelial ovarian cancer (rEOC) patients. Blood samples from 46 age matched healthy controls (HC) were used for comparative analysis. Results revealed, frequency of circulatory CD56(Bright) NK, CD56(Dim) NK, NKT-like, and T cells was reduced with activating receptors while alterations in immune subsets with inhibitory receptors were observed in both groups. Study also highlights differential immune profile of primary and recurrent ovarian cancer patients. We have found increased soluble MICA which might have acted as “decoy” molecule and could be a reason of decrease in NKG2D positive subsets in both groups of patients. Furthermore, elevated level of serum cytokines IL-2, IL-5, IL-6, IL-10, and TNF-α in ovarian cancer patients, might be associated with ovarian cancer progression. Profiling of tumor infiltrated immune cells revealed the reduced level of DNAM-1 positive NK and T cells in both groups than their circulatory counterpart, which might have led to decrease in NK cell’s ability of synapse formation. CONCLUSIONS: The study brings out differential receptor expression profile on CD56(Bright)NK, CD56(Dim)NK, NKT-like, and T cells, cytokines levels and soluble ligands which may be exploited to develop alternate therapeutic approaches for HGSOC patients. Further, few differences in the circulatory immune profiles between pEOC and rEOC cases, indicates the immune signature of pEOC undergoes some changes in circulation that might facilitated the disease relapse. They also maintains some common immune signatures such as reduced expression of NKG2D, high level of MICA as well as IL-6, IL10 and TNF-α, which indicates irreversible immune suppression of ovarian cancer patients. It is also emphasized that a restoration of cytokines level, NKG2D and DNAM-1on tumor infiltrated immune cells may be targeted to develop specific therapeutic approaches for high-grade serous epithelial ovarian cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13048-023-01192-4.
format Online
Article
Text
id pubmed-10268537
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102685372023-06-15 Immune profile of primary and recurrent epithelial ovarian cancer cases indicates immune suppression, a major cause of progression and relapse of ovarian cancer Kumar, Pavan Ranmale, Samruddhi Mehta, Sanket Tongaonkar, Hemant Patel, Vainav Singh, Amit Kumar Mania-Pramanik, Jayanti J Ovarian Res Research BACKGROUND: Ovarian cancer is the third most prevalent cancer in Indian women. Relative frequency of High grade serous epithelial ovarian cancer (HGSOC) and its associated deaths are highest in India which suggests the importance of understanding their immune profiles for better treatment modality. Hence, the present study investigated the NK cell receptor expression, their cognate ligands, serum cytokines, and soluble ligands in primary and recurrent HGSOC patients. We have used multicolor flow cytometry for immunophenotyping of tumor infiltrated and circulatory lymphocytes. Procartaplex, and ELISA were used to measure soluble ligands and cytokines of HGSOC patients. RESULTS: Among the enrolled 51 EOC patients, 33 were primary high grade serous epithelial ovarian cancer (pEOC) and 18 were recurrent epithelial ovarian cancer (rEOC) patients. Blood samples from 46 age matched healthy controls (HC) were used for comparative analysis. Results revealed, frequency of circulatory CD56(Bright) NK, CD56(Dim) NK, NKT-like, and T cells was reduced with activating receptors while alterations in immune subsets with inhibitory receptors were observed in both groups. Study also highlights differential immune profile of primary and recurrent ovarian cancer patients. We have found increased soluble MICA which might have acted as “decoy” molecule and could be a reason of decrease in NKG2D positive subsets in both groups of patients. Furthermore, elevated level of serum cytokines IL-2, IL-5, IL-6, IL-10, and TNF-α in ovarian cancer patients, might be associated with ovarian cancer progression. Profiling of tumor infiltrated immune cells revealed the reduced level of DNAM-1 positive NK and T cells in both groups than their circulatory counterpart, which might have led to decrease in NK cell’s ability of synapse formation. CONCLUSIONS: The study brings out differential receptor expression profile on CD56(Bright)NK, CD56(Dim)NK, NKT-like, and T cells, cytokines levels and soluble ligands which may be exploited to develop alternate therapeutic approaches for HGSOC patients. Further, few differences in the circulatory immune profiles between pEOC and rEOC cases, indicates the immune signature of pEOC undergoes some changes in circulation that might facilitated the disease relapse. They also maintains some common immune signatures such as reduced expression of NKG2D, high level of MICA as well as IL-6, IL10 and TNF-α, which indicates irreversible immune suppression of ovarian cancer patients. It is also emphasized that a restoration of cytokines level, NKG2D and DNAM-1on tumor infiltrated immune cells may be targeted to develop specific therapeutic approaches for high-grade serous epithelial ovarian cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13048-023-01192-4. BioMed Central 2023-06-15 /pmc/articles/PMC10268537/ /pubmed/37322531 http://dx.doi.org/10.1186/s13048-023-01192-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Kumar, Pavan
Ranmale, Samruddhi
Mehta, Sanket
Tongaonkar, Hemant
Patel, Vainav
Singh, Amit Kumar
Mania-Pramanik, Jayanti
Immune profile of primary and recurrent epithelial ovarian cancer cases indicates immune suppression, a major cause of progression and relapse of ovarian cancer
title Immune profile of primary and recurrent epithelial ovarian cancer cases indicates immune suppression, a major cause of progression and relapse of ovarian cancer
title_full Immune profile of primary and recurrent epithelial ovarian cancer cases indicates immune suppression, a major cause of progression and relapse of ovarian cancer
title_fullStr Immune profile of primary and recurrent epithelial ovarian cancer cases indicates immune suppression, a major cause of progression and relapse of ovarian cancer
title_full_unstemmed Immune profile of primary and recurrent epithelial ovarian cancer cases indicates immune suppression, a major cause of progression and relapse of ovarian cancer
title_short Immune profile of primary and recurrent epithelial ovarian cancer cases indicates immune suppression, a major cause of progression and relapse of ovarian cancer
title_sort immune profile of primary and recurrent epithelial ovarian cancer cases indicates immune suppression, a major cause of progression and relapse of ovarian cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10268537/
https://www.ncbi.nlm.nih.gov/pubmed/37322531
http://dx.doi.org/10.1186/s13048-023-01192-4
work_keys_str_mv AT kumarpavan immuneprofileofprimaryandrecurrentepithelialovariancancercasesindicatesimmunesuppressionamajorcauseofprogressionandrelapseofovariancancer
AT ranmalesamruddhi immuneprofileofprimaryandrecurrentepithelialovariancancercasesindicatesimmunesuppressionamajorcauseofprogressionandrelapseofovariancancer
AT mehtasanket immuneprofileofprimaryandrecurrentepithelialovariancancercasesindicatesimmunesuppressionamajorcauseofprogressionandrelapseofovariancancer
AT tongaonkarhemant immuneprofileofprimaryandrecurrentepithelialovariancancercasesindicatesimmunesuppressionamajorcauseofprogressionandrelapseofovariancancer
AT patelvainav immuneprofileofprimaryandrecurrentepithelialovariancancercasesindicatesimmunesuppressionamajorcauseofprogressionandrelapseofovariancancer
AT singhamitkumar immuneprofileofprimaryandrecurrentepithelialovariancancercasesindicatesimmunesuppressionamajorcauseofprogressionandrelapseofovariancancer
AT maniapramanikjayanti immuneprofileofprimaryandrecurrentepithelialovariancancercasesindicatesimmunesuppressionamajorcauseofprogressionandrelapseofovariancancer